Diagnostic value of serum B7-H4 for hepatocellular carcinoma

J Surg Res. 2015 Aug;197(2):301-6. doi: 10.1016/j.jss.2015.04.034. Epub 2015 Apr 16.


Background: Previous studies have suggested the abnormal expression of soluble B7-H4 (sB7-H4) in circulation in cancer patients. The aim of present study was to examine the sB7-H4 expression in serum and to investigate the correlations between sB7-H4 levels and clinicopathologic parameters as well as the survival rate of patients with hepatocellular carcinoma (HCC).

Materials and methods: Circulating sB7-H4 levels in blood specimens from 93 patients with HCC and 55 healthy volunteers were examined by enzyme-linked immunosorbent assay. The association of sB7-H4 levels with clinicopathologic factors, overall survival (OS), and time to recurrence were statistically analyzed.

Results: sB7-H4 levels in HCC patients were significantly higher than that in healthy controls (49.12 ± 3.10 versus 31.66 ± 2.59 ng/mL, P < 0.001). High sB7-H4 levels were correlated with tumor size (P = 0.007), tumor invasion (P = 0.037), tumor differentiation (P = 0.044) and tumor-node metastasis stage (P < 0.001). In addition, high sB7-H4 levels were significantly related to poor OS and higher recurrence probability (P = 0.002, P = 0.014, respectively). High sB7-H4 levels were independent prognostic factors for both OS (hazard ratio = 2.497; 95% confidence interval, 1.133-3.789; P = 0.009) and time to recurrence (hazard ratio = 2.33; 95% confidence interval, 1.247-4.179; P = 0.008).

Conclusions: Detection of sB7-H4 in serum might serve as a clinical predictor in the diagnosis or prediction of clinical outcomes for the patients with HCC.

Keywords: Hepatocellular carcinoma; Prognosis; Soluble B7-H4; Tumor progression.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / diagnosis*
  • Carcinoma, Hepatocellular / mortality
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Liver Neoplasms / blood
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / mortality
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prognosis
  • Survival Analysis
  • V-Set Domain-Containing T-Cell Activation Inhibitor 1 / blood*


  • Biomarkers, Tumor
  • V-Set Domain-Containing T-Cell Activation Inhibitor 1
  • VTCN1 protein, human